How does semaglutide ordering work on BoomRx?

Compounded semaglutide is typically dispensed in multi-dose vials, and a titration program draws escalating doses from those vials as the patient steps up. BoomRx connects clinics to hundreds of 503A formulary products plus 503B outsourcing options through one dashboard, with injectable semaglutide in its weight-management category and oral semaglutide using nanoemulsion delivery announced in January 2026. Concentrations, vial sizes, and which partner fulfills each SKU depend on the network and your account, so confirm the formulary in the live dashboard rather than assuming a fixed catalog.

This page is about ordering workflow, not clinical dosing. The platform's job is to make the right product reach the patient with a correct SIG and licensure handled — not to advise on titration schedules, which are a prescriber decision. What you should evaluate is whether the platform surfaces the per-vial economics, flat-rate shipping impact, and validation that keep a titration program ordering cleanly.

Two failure points dominate semaglutide ordering. The first is pricing visibility: BoomRx markets competitive pricing and average savings versus industry, but per-vial semaglutide rates appear in the provider dashboard after signup, not on boomrx.com. For a business whose margin is the spread on one molecule, model landed cost on your actual SKUs — including the $30 flat cold-chain shipping fee — rather than a headline average. The second is patient-linked workflow: a procurement portal optimizes vendor access; if your team batches dozens of patient-specific refills daily, confirm whether each line ties to a patient with audit depth or stays procurement-scoped.

Fizy Health is built for patient-linked 503A checkout around these pressure points. Per-vial 503A cost shows on each catalog and cart line before checkout, the whole refill day goes into one validated clinic cart, and steady patients can move to auto-ship so a titration program keeps shipping on schedule. Where BoomRx publishes no per-SKU detail publicly, treat concentrations and rates as onboarding questions rather than assumptions.